8-K: Celularity Inc. Faces Nasdaq Delisting Notice Due to Late Quarterly Filing

Celularity Inc. received a notice from Nasdaq for failing to file its Q3 2024 report on time, potentially leading to delisting if compliance is not regained.

Summary

• Celularity Inc. was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, within the extended deadline.
• The company notified Nasdaq on November 21, 2024, that it had not completed the preparation of its financial statements, causing a failure to meet the timely filing requirements.
• Nasdaq issued a formal notice stating that Celularity no longer complies with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1).
• The company's stock and warrants continue to trade on the Nasdaq Capital Market under the symbols CELU and CELUW, respectively, despite the notice.
• Celularity has 60 calendar days, until January 20, 2025, to submit a plan to regain compliance to Nasdaq.
• If the plan is accepted, Celularity has 180 calendar days from the original due date of the Q3 2024 Form 10-Q, until May 13, 2025, to implement the plan.
• There is no guarantee that Celularity will regain compliance or maintain compliance with other Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) due to a failure to meet reporting deadlines, which is a major concern for investors. The lack of completed financial statements and the uncertainty of regaining compliance further contribute to the negative sentiment.

Positives

• The company's stock and warrants continue to trade on the Nasdaq Capital Market despite the delisting notice.
• Celularity has a 60-day period to submit a plan to regain compliance, and if accepted, a further 180 days to implement it.

Negatives

• Celularity failed to file its Q3 2024 Form 10-Q on time, leading to a delisting notice from Nasdaq.
• The company has not completed the preparation of its financial statements, indicating potential internal issues.
• There is no assurance that Celularity will regain compliance with Nasdaq listing requirements.

Risks

• Failure to submit an acceptable plan to Nasdaq by January 20, 2025, could lead to delisting.
• Even with an accepted plan, there is no guarantee that Celularity will be able to regain compliance by May 13, 2025.
• The delisting notice could negatively impact investor confidence and the company's stock price.
• The company may face challenges in raising capital or securing partnerships if it is not compliant with Nasdaq listing requirements.

Future Outlook

The company intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period. However, there can be no assurance that the Company will regain compliance within the compliance period, or maintain compliance with the other Nasdaq listing requirements.

Management Comments

• Robert J. Hariri, M.D., Ph.D., Chairman and CEO, signed the report on behalf of Celularity Inc.

Industry Context

Late filings and delisting notices are not uncommon, particularly for companies facing financial or operational challenges. This situation highlights the importance of timely and accurate financial reporting for maintaining investor confidence and exchange listing status.

Comparison to Industry Standards

• Many companies in the biotech and pharmaceutical sectors face challenges in meeting reporting deadlines, especially during periods of rapid growth or financial restructuring.
• Companies like Sorrento Therapeutics and Cassava Sciences have also faced scrutiny and delays in their financial reporting, highlighting the industry's sensitivity to regulatory compliance.
• The 60-day and 180-day periods for compliance are standard for Nasdaq, but the success of the plan depends on the company's ability to address the underlying issues causing the delay.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty about the company's future.
• Creditors may be concerned about the company's ability to meet its obligations.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Celularity must submit a plan to regain compliance to Nasdaq by January 20, 2025.
• If the plan is accepted, Celularity must implement the plan by May 13, 2025.
• The company will evaluate available options to regain compliance.

Key Dates

Keywords

Delisting, Nasdaq, Compliance, Late Filing, Form 10-Q, Financial Statements, CELU, CELUW